Research programme: TTK inhibitors - Fresh Tracks Therapeutics
Latest Information Update: 26 Sep 2023
At a glance
- Originator Voronoi
- Developer Fresh Tracks Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action TTK protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation